LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-08-08
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of LB-100 when given together with
carboplatin, etoposide, and atezolizumab for the treatment of untreated extensive-stage small
cell lung cancer. Drugs such as carboplatin and etoposide work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. LB-100 has been shown to make anticancer drugs (chemotherapy)
work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A.
Blocking this protein makes the tumor cells that express PP2A divide. This allows standard
chemotherapy drugs such as carboplatin, etoposide, and atezolizumab work better at killing
the tumor cells since these drugs work best at destroying cells that are dividing. Giving
LB-100 in combination with standard chemotherapy drugs may work better to treat
extensive-stage small cell lung cancer compared to standard chemotherapy drugs alone.